Last reviewed · How we verify
RSV Therapeutics LLC — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| XC221 | XC221 | phase 3 | SARS-CoV-2 main protease inhibitor | SARS-CoV-2 main protease | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Addpharma Inc. · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Beijing Minhai Biotechnology Co., Ltd · 1 shared drug class
- Biota Scientific Management Pty Ltd · 1 shared drug class
- Cocrystal Pharma, Inc. · 1 shared drug class
- Ethris GmbH · 1 shared drug class
- IRCCS San Raffaele · 1 shared drug class
- Icahn School of Medicine at Mount Sinai · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for RSV Therapeutics LLC:
- RSV Therapeutics LLC pipeline updates — RSS
- RSV Therapeutics LLC pipeline updates — Atom
- RSV Therapeutics LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). RSV Therapeutics LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rsv-therapeutics-llc. Accessed 2026-05-16.